Appeal No. 95-2419
Application 07/850,770
11 and 12 for our consideration. Claims 11 and 12 as well as allowed claim 1 from which
these claims depend read as follows:
1. A composition comprising a mutant recombinant human immunodeficiency virus
type 1 (HIV-1) envelope glycoprotein which is mutated in its primary amino acid sequence
with respect to a wild type HIV-1 envelope glycoprotein, said mutant glycoprotein including
two or more N-linked carbohydrate consensus amino acid sequence mutations so as to
effect partial deglycosylation, said mutation being positioned between the C terminus of
gp120 and the Cys at the N-terminal side of the gp120 cysteine loop containing the third
hypervariable sequence (V3), said Cys being approximately at amino acid position 296,
said mutant glycloprotein being sufficiently deglycosylated such that the total molecular
mass of the mutant gp120 component is less than 90% of the corresponding fully
glycosylated wild type gp120 component, said mutant glycoprotein being effective, when
present as a component of a complete HIV virion, to enable viral infectivity.
11. A vaccine for use in protection of a human against infection with HIV-1, said
vaccine comprising the mutant glycoprotein composition of claim 1.
12. A vaccine for use in treatment of a human infected with HIV-1, said vaccine
comprising the mutant glycoprotein composition of claim 1.
The documents relied upon by the examiner as of the time of the Supplemental
Examiner's Answer are:
Koff et al. (Koff), “Development and Testing of AIDS Vaccines,” Science, Vol. 341,
pp. 426-32 (July 1988).
Schild et al. (Schild), “Modern Vaccines,” The Lancet, Vol. 335, pp. 1081-84,
May 1990).
Flier et al. (Flier), “Vaccines Against Human Immunodeficiency Virus-Progress and
Prospects,” The New England Journal of Medicine, Vol. 329, No. 19, pp. 1400-05
(Nov. 1993).
Cohen, “Jitters Jeopardize AIDS Vaccine Trials,” Science, Vol. 262, pp. 980-81
(Nov. 1993).
2
Page: Previous 1 2 3 4 5 6 7 8 9 10 Next
Last modified: November 3, 2007